Delcath Systems Participation at H.C. Wainwright BioConnect Investor Conference
Delcath Systems, Inc. will be attending the H.C. Wainwright 4th Annual BioConnect Investor Conference on May 19, 2026, in New York City. The company specializes in interventional oncology for the treatment of liver cancers.
QUEENSBURY, N.Y.–(BUSINESS WIRE)–Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that management will be attending the H.C. Wainwright 4th Annual BioConnect Investor Conference on Tuesday, May 19, 2026 at Nasdaq in New York, NY. About Delcath Systems, Inc., HEPZATO KIT and CHEMOSAT Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and